Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to treatment start\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Participants with known brain metastases may be enrolled in this study if radiation therapy and/or surgery have been completed with a minimum of  weeks of stable disease demonstrated on evaluation by magnetic resonance imaging (MRI); such participants must no longer require treatment with corticosteroids or enzyme inducing anti-epileptic medications for their central nervous system (CNS) disease
Central nervous system (CNS) involvement unless they meet ALL of the following criteria:\r\n* >=  days from prior therapy completion (including radiation and/or surgery) to registration\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Participants with central nervous system (CNS) involvement unless they meet ALL of the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases\r\n* Baseline screening for CNS metastases is not required unless presence of signs and/or symptoms of involvement
Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Patients with uncontrolled central nervous system (CNS) metastatic involvement; however, patients with metastatic CNS tumors may participate in this study if the patient is:\r\n* >  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable with respect to the CNS tumor at the time of screening\r\n* Not receiving steroid therapy\r\n* Not receiving anti-convulsive medications that were started for brain metastases
Subjects with primary central nervous system (CNS) tumor or CNS tumor involvement. However, subjects with metastatic CNS tumors may participate in this study if the subject is: >  weeks from prior therapy completion (including radiation and/or surgery); clinically stable with respect to the CNS tumor at the time of study entry; not receiving steroid therapy in treating CNS tumor or CNS tumor involvement; not receiving anti-convulsive medications (that were started for brain metastases).
Central nervous system (CNS) involvement unless they meet ALL of the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Patients with untreated or symptomatic metastatic central nervous system (CNS) disease; however patients with CNS involvement may participate if:\r\n* Clinically stable with respect to the CNS tumor at the time of screening and >  weeks from prior therapy completion (including radiation and/or surgery) to the start of study treatment\r\n* Not on steroid therapy\r\n* Not receiving enzyme inducing anti-epileptic medications that were started for brain metastases (these include carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine, topiramate, and vigabatrin)
Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; however, patients with CNS metastases (including brain metastases) are eligible for the study provided they are clinically stable and have met ALL of the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Patients with CNS involvement unless they meet ALL of the following criteria:\r\n* At least  weeks from prior therapy completion ((including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Patients with central nervous system (CNS) involvement may participate if the patient is:\r\n* >=  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable with respect to the CNS tumor at the time of screening\r\n* Not receiving steroid therapy
Patients with untreated symptomatic brain metastases are excluded; however, patients with metastatic central nervous system (CNS) tumors may participate in this trial, if the patient is >  weeks from therapy completion (including radiation and/or surgery), is clinically stable at the time of study entry and is not receiving corticosteroid therapy for the brain metastases (mets)
Patients with untreated or symptomatic metastatic central nervous system (CNS) disease; however patients with CNS involvement may participate if:\r\n* Clinically stable with respect to the CNS tumor at the time of screening and >  weeks from prior therapy completion (including radiation and/or surgery) to the start of study treatment\r\n* Not receiving steroid therapy \r\n* Not receiving enzyme inducing anti-epileptic medications that were started for brain metastases (these include carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine, topiramate, and vigabatrin)
Patient with CNS involvement unless he/she is at least  weeks from prior therapy completion to starting the study treatment and has stable CNS tumor at time of screening and not receiving steroids and/or enzyme inducing ant-epileptic medications for brain metastases
Patients who have central nervous system (CNS) involvement unless they meet ALL of the following criteria:\r\n* >=  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
Patient with CNS involvement unless they are at least  weeks from prior therapy completion to starting the study treatment and have stable CNS tumor at the time of screening and not receiving steroids and/or enzyme inducing anti-epileptic medications for brain metastases
Patients with central nervous system (CNS) involvement may participate if they meet all the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable with respect to the CNS tumor at the time of screening
Patients with central nervous system (CNS) involvement unless they meet all of the following criteria: a. At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment. b. Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases.
Patients with untreated brain metastases are excluded; however, patients with metastatic central nervous system (CNS) tumors may participate in this trial, if the patient is >  weeks from therapy completion (incl. radiation and/or surgery), is clinically stable at the time of study entry and is receiving low dosage corticosteroid therapy
Patients with central nervous system (CNS) involvement may participate if the patient meets all of the following criteria:\r\n* At least  weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\r\n* Clinically stable with respect to the CNS tumor at the time of screening\r\n* Not receiving steroid therapy\r\n* Not receiving enzyme inducing anti-epileptic medications that were started for brain metastases
Patients with central nervous system (CNS) involvement may participate if:\r\n* Clinically stable with respect to the CNS tumor at the time of screening and >  weeks from prior therapy completion (including radiation and/or surgery) to the start of study treatment\r\n* Not receiving steroid therapy\r\n* Not receiving enzyme inducing anti-epileptic medications that were started for brain metastases (these include carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine, topiramate, and vigabatrin)
Patients with untreated brain metastases are excluded; however, patients with metastatic central nervous system (CNS) tumors may participate in this trial, if the patient is >  weeks from therapy completion (including radiation and/or surgery), is clinically stable at the time of study entry and is not receiving corticosteroid therapy
Patients with untreated brain metastases are excluded; however, patients with metastatic central nervous system (CNS) tumors may participate in this trial, if the patient is >  weeks from therapy completion (including [incl.] radiation and/or surgery), is clinically stable at the time of study entry, and is not receiving corticosteroid therapy
Patients with primary central nervous system (CNS) tumor or CNS tumor involvement; however, patients with metastatic CNS tumors may participate in this study if the patient is: \r\n* >  weeks from prior therapy completion (including radiation and/or surgery)\r\n* Clinically stable with respect to the CNS tumor at the time of study entry \r\n* Not receiving steroid therapy in treating CNS tumor or CNS tumor involvement\r\n* Not receiving anti-convulsive medications (that were started for brain metastases)
